|
tTg New Generation - a novel approach to Celiac disease testing
Tissue Transglutaminase (tTg) has been identified as the major
target antigen in endomysium in 1997 by Dieterich and Schuppan et.al.
Over the last 10 years, gliadin testing has been replaced by tTg
testing thus, celiac disease diagnosis has risen to a sensitivity
and specificity level unknown before.
Even after this main serological discovery, a vast majority of
celiac patients still remain undetected (ratio of known to unknown
CD is 1 to 7 and there’s a mean delay on a CD diagnosis of 5 to 11
years.
Several theories about the “iceberg model” were published, and
studies have shown that CD also exists in different underestimated
forms referred to as potential, latent and silent CD.
Meta-analyses of current studies indicate that celiac disease
affects 1% of the population worldwide. Risk groups (like DM type 1
and Osteoporosis) have an even higher prevalence (from 1:20 to 1:7).
AESKULISA® tTg New Generation now sets new standards in
sensitivity and specificity of celiac disease diagnosis.
The results of a recent Multi-Center Celiac Serology Study
undertaken to define the optimal serological screening approach to
Celiac Disease clearly showed that dual or combined isotype (IgA+IgG)
transglutaminase screening can be advocated as a sensitive and
specific alternative to endomysial antibody testing in the
assessment of Celiac Disease. AESKULISA® tTg ELISA kits performed
excellent. AESKULISA® Celicheck even placed first as the best dual
isotype transglutaminase kit of all assays tested.
The reason is obvious: AESKULIA® tTg New Generation ELISA kits show
a unique composition. Human recombinant tissue transglutaminase is
cross-linked with gliadin-specific peptides resulting in the
creation of neo-epitopes of tTg. The tests are highly specific as no
cross-reactions with gliadin occur.
Thus the AESKULIA® tTg New Generation tests are the only available
tTg test to mimic the physiologically relevant tTg enzyme complex –
offering a sensitivity and specificity level unknown before.
-
AESKULISA® tTg IgA sets new standards in sensitivity.
-
AESKULISA® tTg IgG is indispensable in cases of celiac patients
with selective IgA deficiency.
-
AESKULISA® CeliCheck for the combined determination of IgA and
IgG autoantibodies is ideal for screening purposes.
Features of our tTg New generation kits are:
-
For
detection of tissue transglutaminase antibodies, a new
generation of tTg tests is available: by presenting neo-epitopes
of tTg, the sensitivity of the tests could be markedly
increased. Neo epitopes of tTg are induced by adding gliadin-specific
peptides.
-
At
the same time, the tests are highly specific as no
cross-reactions with gliadin occur.
-
In
addition, the new generation tTg assays employ human recombinant
tissue transglutaminase, which ensures maximum specificity and
sensitivity as compared to the guinea pig antigen, which shares
only 80% homology with its human counterpart.
-
US
FDA approved kits
Due to
its special formulation, the tTg New generation is able to detect 3
different types of antibo¬dies:
For more information about the new possibilities in celiac disease
testing and about the unique composition of the AESKULIA® tTg New
Generation ELISA kits please mail us at info@immunoshop.com
|
